SCHEMBL20249272

SCHEMBL20249272

CC1(C)CN(c2ccc(C(C)(C)C)nc2)CCNC1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 6/20 0.34
CHRNA4 P43681 6/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CDK4 P11802 6/20 0.34
CCND1 P24385 6/20 0.34
CCNT1 O60563 2/20 0.34
CCND3 P30281 2/20 0.34
CDK9 P50750 2/20 0.34
CDK6 Q00534 2/20 0.34
CDK7 P50613 1/20 0.33
CCNH P51946 1/20 0.33
MNAT1 P51948 1/20 0.33
CDK5 Q00535 1/20 0.33
CDK5R1 Q15078 1/20 0.33
PARP1 P09874 1/20 0.32
PARP2 Q9UGN5 1/20 0.32
CDK2 P24941 3/20 0.32
CCNE1 P24864 2/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20037990 0.83 ELANE (0.40) CHRNB2CHRNA4CHRNB4CHRNA3CDK4
SCHEMBL18291342 0.82 MTOR (0.39) CHRNB2CHRNA4CHRNB4CHRNA3CDK4
SCHEMBL20255216 0.82 CHRNB2 (0.36) CHRNB2CHRNA4CHRNB4CHRNA3CDK4
SCHEMBL20037603 0.80 CDK4 (0.35) CHRNB2CHRNA4CHRNB4CHRNA3CDK4
SCHEMBL20249102 0.79 CDK4 (0.43) CHRNB2CHRNA4CHRNB4CHRNA3CDK4
SCHEMBL20249114 0.79 CCNT1 (0.46) CHRNB2CHRNA4CDK4CCND1CCNT1
SCHEMBL12145921 0.75 CHRNB2 (0.58) CHRNB2CHRNA4CDK4CCND1
SCHEMBL20249255 0.74 CYP1A2 (0.41) CDK4CCND1CCNT1CCND3CDK9
SCHEMBL20249245 0.73 CHRNB2 (0.51) CHRNB2CHRNA4CHRNB4CHRNA3CDK4
SCHEMBL20249236 0.73 CHRNB2 (0.62) CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 CHRNB2 4863/4885CHRNA4 4628/4885CHRNB4 4823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.